Stockscreener 앱 받기
20.88
4.09%
-0.89
시간 외 거래:
20.92
0.04
+0.19%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BIOAGE Labs Inc (BIOA) Income Statement - TradingKey
TradingKey - TradingKey
BIOAGE Labs Inc (BIOA) Balance Sheet - TradingKey
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BIOA|BIOAGE Labs Inc|Price:21.770|Chg%:-0.130 - TradingKey
BioAge Labs, Inc. Revenue Breakdown – NASDAQ:BIOA - TradingView
BIOAGE Labs Inc (BIOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G - TradingView
BIOA Q1 2026 Earnings: EPS Beat Surprise but Stock Drops on Pre-Revenue StatusInterim Report - dars.gov.et
HitGen partner BioAge begins phase 2 trial of BGE-102 By Investing.com - Investing.com Nigeria
HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 - TradingView
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - The Manila Times
HitGen partner BioAge begins phase 2 trial of BGE-102 - Investing.com
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction – Company AnnouncementFT.com - Financial Times
Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment - Traders Union
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - simplywall.st
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge advances inflammaging drug into Phase 2 - Longevity.Technology
Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Frau - GuruFocus
Price to earnings forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
Bioage Labs stock hits 52-week high at 25.8 USD - Investing.com
Bioage Labs stock hits 52-week high at 25.8 USD By Investing.com - Investing.com Nigeria
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Sahm
BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com - Investing.com India
Form 4 Bioage Labs Inc For: 1 July By Investing.com - Investing.com Nigeria
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: - GuruFocus
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing - Moomoo
BioAge Labs principal accounting officer sells $1.57m in stock - Investing.com
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs Inc. (BIOA) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineFinal Results - dars.gov.et
BioAge Labs Hits Day High with 9.98% Surge, Outperforming Market - MarketsMojo
BioAge Labs (BIOA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Biotech Development StageMid-Term Outlook - dars.gov.et
BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale - Stock Titan
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Yahoo Finance
Form 144 BioAge Labs For: 29 June By Investing.com - Investing.com Nigeria
BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000E Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2500 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
0.30%
2.01%
자본화:
|
볼륨(24시간):